Hereditary diffuse gastric cancer: Association with lobular breast cancer

Familial Cancer

Volumn 7, Issue 1, 2008, Pages 73-82

  Schrader, Kasmintan A ^a,b   Masciari, Serena ^c   Boyd, Niki ^b   Wiyrick, Sara ^d   Kaurah, Pardeep ^b   Senz, Janine ^a   Burke, Wylie ^d   Lynch, Henry T ^e   Garber, Judy E ^c   Huntsman, David G ^a,b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b BRITISH COLUMBIA CANCER AGENCY   (Canada)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

^e CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

CDH1 mutation; Diffuse gastric cancer; E cadherin mutation; Hereditary diffuse gastric cancer (HDGC); Lobular breast cancer; Prophylactic total gastrectomy; Screening

Indexed keywords

UVOMORULIN; CADHERIN; CDH1 PROTEIN, HUMAN;

ADULT; BREAST CANCER; CDH1 GENE; CHROMOSOME 16Q; CLINICAL ARTICLE; CONFERENCE PAPER; DISEASE ASSOCIATION; FAMILIAL CANCER; FEMALE; GENE; GENE MUTATION; HEREDITARY DIFFUSE GASTRIC CANCER; HUMAN; LOBULAR BREAST CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; STOMACH CANCER; BREAST TUMOR; CASE REPORT; GASTRECTOMY; GENE EXPRESSION REGULATION; GENETIC COUNSELING; GENETIC PREDISPOSITION; GENETICS; LUNG CARCINOMA; MASS SCREENING; METABOLISM; MIDDLE AGED; MULTIPLE CANCER; MUTATION; REVIEW; RISK; STOMACH TUMOR; SYNDROME;

BREAST NEOPLASMS; CADHERINS; CARCINOMA, LOBULAR; FEMALE; GASTRECTOMY; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC COUNSELING; GENETIC PREDISPOSITION TO DISEASE; GERM-LINE MUTATION; HUMANS; MASS SCREENING; MIDDLE AGED; NEOPLASMS, MULTIPLE PRIMARY; RISK; STOMACH NEOPLASMS; SYNDROME;

EID: 46449107403     PISSN: 13899600     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10689-007-9172-6     Document Type: Conference Paper

References (90)

1. KD Crew AI Neugut 2006 Epidemiology of gastric cancer World J Gastroenterol 3 354 362
2. DE Henson C Dittus M Younes 2004 Differential trends in the intestinal and diffuse types of gastric carcinoma in the United States, 1973-2000: increase in the signet ring cell type Arch Pathol Lab Med 7 765 770
3. P Guilford J Hopkins J Harraway 1998 E-cadherin germline mutations in familial gastric cancer Nature 6674 402 405
4. P Kaurah A. MacMillan N Boyd 2007 Founder and recurrent CDH1 mutations in families with hereditary diffuse gastric cancer JAMA 21 2360 2372
5. G Keller H Vogelsang I Becker 1999 Diffuse type gastric and lobular breast carcinoma in a familial gastric cancer patient with an E-cadherin germline mutation Am J Pathol 2 337 342
6. G Suriano S Yew P Ferreira 2005 Characterization of a recurrent germ line mutation of the E-cadherin gene: implications for genetic testing and clinical management Clin Cancer Res 15 5401 5409
7. C Oliveira MC Bordin N Grehan 2002 Screening E-cadherin in gastric cancer families reveals germline mutations only in hereditary diffuse gastric cancer kindred Hum Mutat 5 510 517
8. AR Brooks-Wilson P Kaurah G Suriano 2004 Germline E-cadherin mutations in hereditary diffuse gastric cancer: assessment of 42 new families and review of genetic screening criteria J Med Genet 7 508 517
9. S Masciari N Larsson J Senz 2007 Germline E-Cadherin mutations in familial lobular breast cancer J Med Genet 44 726 731
10. F Graziano B Humar P Guilford 2003 The role of the E-cadherin gene (CDH1) in diffuse gastric cancer susceptibility: from the laboratory to clinical practice Ann Oncol 12 1705 1713
11. G Berx KF Becker H Hofler 1998 Mutations of the human E-cadherin (CDH1) gene Hum Mutat 4 226 237
12. H Aberle H Schwartz R Kemler 1996 Cadherin-catenin complex: protein interactions and their implications for cadherin function J Cell Biochem 4 514 523
13. MA Thoreson PZ Anastasiadis JM Daniel 2000 Selective uncoupling of p120(ctn) from E-cadherin disrupts strong adhesion J Cell Biol 1 189 202
14. K Xiao RG Oas CM Chiasson 2007 Role of p120-catenin in cadherin trafficking Biochim Biophys Acta 1 8 16
15. K Vleminckx L Vakaet Jr M Mareel 1991 Genetic manipulation of E-cadherin expression by epithelial tumor cells reveals an invasion suppressor role Cell 1 107 119
16. BP Wijnhoven WN Dinjens M Pignatelli 2000 E-cadherin-catenin cell-cell adhesion complex and human cancer Br J Surg 8 992 1005
17. A Novak S Dedhar 1999 Signaling through beta-catenin and Lef/Tcf Cell Mol Life Sci 5-6 523 537
18. S Orsulic O Huber H Aberle 1999 E-cadherin binding prevents beta-catenin nuclear localization and beta-catenin/LEF-1-mediated transactivation J Cell Sci Pt 8 1237 1245
19. K Aoki MM Taketo 2007 Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene J Cell Sci Pt 19 3327 3335
20. F Carneiro DG Huntsman TC Smyrk 2004 Model of the early development of diffuse gastric cancer in E-cadherin mutation carriers and its implications for patient screening J Pathol 2 681 687
21. WJ De Leeuw G Berx CB Vos 1997 Simultaneous loss of E-cadherin and catenins in invasive lobular breast cancer and lobular carcinoma in situ J Pathol 4 404 411
22. KF Becker MJ Atkinson U Reich 1994 E-cadherin gene mutations provide clues to diffuse type gastric carcinomas Cancer Res 14 3845 3852
23. KF Becker H Hofler 1995 Frequent somatic allelic inactivation of the E-cadherin gene in gastric carcinomas J Natl Cancer Inst 14 1082 1084
24. JC Machado P Soares F Carneiro 1999 E-cadherin gene mutations provide a genetic basis for the phenotypic divergence of mixed gastric carcinomas Lab Invest 79 459 465
25. Carneiro F, Oliveira C, Suriano G et al (2007) Molecular pathology of familial gastric cancer. J. Clin. Pathol
26. WM Grady J Willis PJ Guilford 2000 Methylation of the CDH1 promoter as the second genetic hit in hereditary diffuse gastric cancer Nat Genet 1 16 17
27. DL Thull VG Vogel 2004 Recognition and management of hereditary breast cancer syndromes Oncologist 1 13 24
28. DS Rosman V Kaklamani B Pasche 2007 New insights into breast cancer genetics and impact on patient management Curr Treat Options Oncol 1 61 73
29. CHEK2 Breast Cancer Case-Control Consortium 2004 CHEK2*1100delC and susceptibility to breast cancer: a collaborative analysis involving 10,860 breast cancer cases and 9,065 controls from 10 studies Am J Hum Genet 6 1175 1182
30. S Seal D Thompson A Renwick 2006 Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles Nat Genet 11 1239 1241
31. N Rahman S Seal D Thompson 2007 PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene Nat Genet 2 165 167
32. M Ahmed N Rahman 2006 ATM and breast cancer susceptibility Oncogene 43 5906 5911
33. G Arpino VJ Bardou GM Clark 2004 Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome Breast Cancer Res 3 R149 156
34. K Allen-Brady NJ Camp JH Ward 2005 Lobular breast cancer: excess familiality observed in the Utah Population Database Int J Cancer 4 655 661
35. SR Lakhani BA Gusterson J Jacquemier 2000 The pathology of familial breast cancer: histological features of cancers in families not attributable to mutations in BRCA1 or BRCA2 Clin Cancer Res 3 782 789
36. R Moll M Mitze UH Frixen 1993 Differential loss of E-cadherin expression in infiltrating ductal and lobular breast carcinomas Am J Pathol 6 1731 1742
37. G Berx F Van Roy 2001 The E-cadherin/catenin complex: an important gatekeeper in breast cancer tumorigenesis and malignant progression Breast Cancer Res 5 289 293
38. G Berx AM Cleton-Jansen K Strumane 1996 E-cadherin is inactivated in a majority of invasive human lobular breast cancers by truncation mutations throughout its extracellular domain Oncogene 9 1919 1925
39. G Berx AM Cleton-Jansen F Nollet 1995 E-cadherin is a tumour/invasion suppressor gene mutated in human lobular breast cancers EMBO J 24 6107 6115
40. S Droufakou V Deshmane R Roylance 2001 Multiple ways of silencing E-cadherin gene expression in lobular carcinoma of the breast Int J Cancer 3 404 408
41. JC Machado C Oliveira R Carvalho 2001 E-cadherin gene (CDH1) promoter methylation as the second hit in sporadic diffuse gastric carcinoma Oncogene 12 1525 1528
42. B Humar T Toro F Graziano 2002 Novel germline CDH1 mutations in hereditary diffuse gastric cancer families Hum Mutat 5 518 525
43. D Sarrio G Moreno-Bueno D Hardisson 2003 Epigenetic and genetic alterations of APC and CDH1 genes in lobular breast cancer: relationships with abnormal E-cadherin and catenin expression and microsatellite instability Int J Cancer 2 208 215
44. N Rahman JG Stone G Coleman 2000 Lobular carcinoma in situ of the breast is not caused by constitutional mutations in the E-cadherin gene Br J Cancer 3 568 570
45. S Salahshor L Haixin H Huo 2001 Low frequency of E-cadherin alterations in familial breast cancer Breast Cancer Res 3 199 207
46. H Lei S Sjoberg-Margolin S Salahshor 2002 CDH1 mutations are present in both ductal and lobular breast cancer, but promoter allelic variants show no detectable breast cancer risk Int J Cancer 2 199 204
47. PD Pharoah P Guilford C Caldas 2001 Incidence of gastric cancer and breast cancer in CDH1 (E-cadherin) mutation carriers from hereditary diffuse gastric cancer families Gastroenterology 6 1348 1353
48. B Fisher J Costantino C Redmond 1989 A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors N Engl J Med 8 479 484
49. SR Land DL Wickerham JP Costantino 2006 Patient-reported symptoms and quality of life during treatment with tamoxifen or raloxifene for breast cancer prevention: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial JAMA 23 2742 2751
50. Wolmark N, Dunn BK (2001) The role of tamoxifen in breast cancer prevention: issues sparked by the NSABP Breast Cancer Prevention Trial (P-1). Ann NY Acad Sci 99-108
51. TR Rebbeck T Friebel HT Lynch 2004 Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group J Clin Oncol 6 1055 1062
52. M Robson T Svahn B McCormick 2005 Appropriateness of breast-conserving treatment of breast carcinoma in women with germline mutations in BRCA1 or BRCA2: a clinic-based series Cancer 1 44 51
53. MC van Kouwen JP Drenth WJ Oye 2004 [18F]Fluoro-2-deoxy-d-glucose positron emission tomography detects gastric carcinoma in an early stage in an asymptomatic E-cadherin mutation carrier Clin Cancer Res 19 6456 6459
54. D Shaw V Blair A Framp 2005 Chromoendoscopic surveillance in hereditary diffuse gastric cancer: an alternative to prophylactic gastrectomy? Gut 4 461 468
55. DG Huntsman F Carneiro FR Lewis 2001 Early gastric cancer in young, asymptomatic carriers of germ-line E-cadherin mutations N Engl J Med 25 1904 1909
56. JA Norton CM Ham J Van Dam 2007 CDH1 truncating mutations in the E-cadherin gene: an indication for total gastrectomy to treat hereditary diffuse gastric cancer Ann Surg 6 873 879
57. HT Lynch W Grady G Suriano 2005 Gastric cancer: new genetic developments J Surg Oncol 3 114 133 discussion 133
58. T Sjoblom S Jones LD Wood 2006 The consensus coding sequences of human breast and colorectal cancers Science 5797 268 274
59. A Antoniou PD Pharoah S Narod 2003 Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies Am J Hum Genet 5 1117 1130
60. A Jakubowska K Nej T Huzarski 2002 BRCA2 gene mutations in families with aggregations of breast and stomach cancers Br J Cancer 8 888 891
61. Cancer risks in BRCA2 mutation carriers. The Breast Cancer Linkage Consortium (1999) J Natl Cancer Inst 15:1310-1316
62. A Figer L Irmin R Geva 2001 The rate of the 6174delT founder Jewish mutation in BRCA2 in patients with non-colonic gastrointestinal tract tumours in Israel Br J Cancer 4 478 481
63. HA Risch JR McLaughlin DE Cole 2001 Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer Am J Hum Genet 3 700 710
64. MS Brose TR Rebbeck KA Calzone 2002 Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program J Natl Cancer Inst 18 1365 1372
65. FM Giardiello JD Brensinger AC Tersmette SN Goodman GM Petersen SV Booker M Cruz-Correa JA Offerhaus 2000 Very high risk of cancer in familial Peutz-Jeghers syndrome Gastroenterology 6 1447 1453
66. TM Starink JP van der Veen F Arwert 1986 The Cowden syndrome: a clinical and genetic study in 21 patients Clin Genet 3 222 233
67. M.H. Brownstein M. Wolf J.B Bikowski 1978 Cowden's disease: a cutaneous marker of breast cancer Cancer 6 2393 2398
68. LS Hamby EY Lee RW Schwartz 1995 Parathyroid adenoma and gastric carcinoma as manifestations of Cowden's disease Surgery 1 115 117
69. JM Birch RD Alston RJ McNally 2001 Relative frequency and morphology of cancers in carriers of germline TP53 mutations Oncogene 34 4621 4628
70. A Chompret A Abel D Stoppa-Lyonnet 2001 Sensitivity and predictive value of criteria for p53 germline mutation screening J Med Genet 1 43 47
71. G Keller H Vogelsang I Becker 2004 Germline mutations of the E-cadherin(CDH1) and TP53 genes, rather than of RUNX3 and HPP1:contribute to genetic predisposition in German gastric cancer patients J Med Genet 6 e89
72. IJ Kim HC Kang Y Shin 2004 A TP53-truncating germline mutation (E287X) in a family with characteristics of both hereditary diffuse gastric cancer and Li-Fraumeni syndrome J Hum Genet 49 591 595
73. C Oliveira P Ferreira S Nabais 2004 E-Cadherin (CDH1) and p53 rather than SMAD4 and Caspase-10 germline mutations contribute to genetic predisposition in Portuguese gastric cancer patients Eur J Cancer 12 1897 1903
74. K Kimura K Shinmura K Yoshimura 2000 Absence of germline CHK2 mutations in familial gastric cancer Jpn J Cancer Res 9 875 879
75. S Shimoyama F Aoki M Kawahara 2004 Early gastric cancer development in a familial adenomatous polyposis patient Dig Dis Sci 2 260 265
76. E Dulaimi J Hillinck I de Ibanez Caceres 2004 Tumor suppressor gene promoter hypermethylation in serum of breast cancer patients Clin Cancer Res 18 Pt 1 6189 6193
77. M Shinozaki DS Hoon AE Giuliano 2005 Distinct hypermethylation profile of primary breast cancer is associated with sentinel lymph node metastasis Clin Cancer Res 6 2156 2162
78. Geary J, Sasieni P, Houlston R et al (2007) Gene-related cancer spectrum in families with hereditary non-polyposis colorectal cancer (HNPCC). Fam Cancer
79. JI Risinger JC Barrett P Watson 1996 Molecular genetic evidence of the occurrence of breast cancer as an integral tumor in patients with the hereditary nonpolyposis colorectal carcinoma syndrome Cancer 9 1836 1843
80. RJ Scott M McPhillips CJ Meldrum 2001 Hereditary nonpolyposis colorectal cancer in 95 families: differences and similarities between mutation-positive and mutation-negative kindreds Am J Hum Genet 1 118 127
81. PJ Westenend R Schutte MM Hoogmans 2005 Breast cancer in an MSH2 gene mutation carrier Hum Pathol 12 1322 1326
82. I Spagnoletti C Pizzi A Galietta 2004 Loss of hMSH2 expression in primary breast cancer with p53 alterations Oncol Rep 4 845 851
83. AF Haerer JF Jackson CG Evers 1969 Ataxia-telangiectasia with gastric adenocarcinoma JAMA 10 1884 1887
84. A Watanabe H Hanazono H Sogawa 1977 Stomach cancer of a 14-year-old boy with ataxia-telangiectasia Tohoku J Exp Med 2 127 131
85. WL Bigbee RG Langlois M Swift 1989 Evidence for an elevated frequency of in vivo somatic cell mutations in ataxia telangiectasia Am J Hum Genet 3 402 408
86. D Thompson S Duedal J Kirner 2005 Cancer risks and mortality in heterozygous ATM mutation carriers J Natl Cancer Inst 11 813 822
87. Y Milo AA Deutsch S Zahavi 1994 Xeroderma pigmentosum with recurrent infiltrating ductal carcinoma of breast Postgrad Med J 821 240 241
88. L Puig R Marti X Matias-Guiu 1985 Gastric adenocarcinoma in a patient with xeroderma pigmentosum Br J Dermatol 5 632 633
89. H Tsuchiya K Tomita M Ohno 1991 Werner's syndrome combined with quintuplicate malignant tumors: a case report and review of literature data Jpn J Clin Oncol 2 135 142
90. M Wirtenberger B Frank K Hemminki 2006 Interaction of Werner and Bloom syndrome genes with p53 in familial breast cancer Carcinogenesis 8 1655 1660